VYEPTI® (eptinezumab-jjmr) represents a paradigm shift in chronic migraine prevention, offering Physicians and their patients the first and only intravenous CGRP antagonist with proven efficacy, rapid onset of action, and sustained therapeutic benefits.
This white paper provides evidence-based insights into VYEPTI’s clinical profile, positioning it as a compelling first-line and alternative treatment option for patients with chronic migraine.
Key Clinical Advantages
Rapid Onset: Therapeutic benefits observable as early as Day 1 post-infusion[1] [2]
Sustained Efficacy: Quarterly dosing with consistent prevention through 3-month intervals[3] [4]
Superior Response Rates: Up to 61.4% of chronic migraine patients achieve ≥50% reduction in monthly migraine days[1] [2]
100% Bioavailability: Intravenous delivery ensures complete drug availability compared to 50-82% with subcutaneous alternatives[5]
Excellent Tolerability: <2% discontinuation rate due to adverse events in clinical trials[6]
The Clinical Burden of Chronic Migraine
Epidemiology and Impact
Chronic migraine affects approximately 2-4% of the global population, representing a significant neurological[7] disorder characterized by ≥15 headache days per month for >3 months, with ≥8 days meeting migraine criteria.[8]
The economic burden is substantial, with migraine costing American employers approximately $13 billion[9] annually due to missed workdays and impaired function. Patients with chronic migraine incur average 3-month[10] headache-related costs of $1,036 compared to $383 for episodic migraine.
Diagnostic Criteria (ICHD-3)
According to the International Classification of Headache Disorders, 3rd edition (ICHD-3), chronic migraine is[8] diagnosed when patients experience:
- Headache (migraine-like or tension-type-like) on ≥15 days/month for >3 months
- History of at least five attacks fulfilling migraine without aura criteria
- On ≥8 days/month for >3 months, headache meets migraine criteria or responds to triptan/ergot treatment
- Not better accounted for by another disorder
Unmet Medical Need
Traditional preventive therapies often provide insufficient efficacy, with many patients experiencing inadequate response, intolerable side effects, or treatment discontinuation. The need for innovative, targeted therapies with superior efficacy and tolerability profiles has driven the development of CGRP-targeted interventions.
CGRP Pathophysiology in Migraine
The CGRP System
Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide with two isoforms (α and β) that plays a [11] [12] central role in migraine pathophysiology.
CGRP is released from trigeminal neurons and acts through [12] specific G protein-coupled receptors formed in complex with receptor activity-modifying proteins.
Mechanism in Migraine Pathogenesis [11]
CGRP contributes to migraine through multiple mechanisms :
- Peripheral Sensitization: CGRP release from trigeminal terminals causes neurogenic inflammation, vasodilation, and mast cell degranulation
- Central Sensitization: CGRP modulates pain transmission in the trigeminal nucleus caudalis and thalamic regions
- Vascular Effects: CGRP induces significant vasodilation in meningeal vessels
- Nociceptor Activation: Direct sensitization of trigeminal nociceptors
Clinical Evidence for CGRP’s Role
Multiple lines of evidence support CGRP’s critical role in migraine [11]:
- Elevated CGRP levels during migraine attacks normalize after successful sumatriptan treatment
- Intravenous CGRP administration induces migraine-like headaches in susceptible patients
- Sumatriptan can reverse CGRP-induced vasodilation and headaches
VYEPTI: Mechanism of Action and Pharmacology
Molecular Target and Binding
Eptinezumab is a recombinant humanized IgG1 monoclonal antibody that binds with high affinity to both α and β [13] forms of human CGRP ligand (4 and 3 pM Kd, respectively).
This binding prevents CGRP from activating its [14] [13] receptors and initiating the downstream cascade of physiological events linked to migraine attacks.
Pharmacokinetic Advantages
Intravenous Administration Benefits:
- 100% bioavailability via IV route versus 50-82% for subcutaneous CGRP inhibitors[5]
- Immediate therapeutic levels achieved within 30 minutes post-infusion[14]
- Elimination half-life of approximately 27 days, supporting quarterly dosing[14]
Selectivity Profile:
- >100,000-fold selectivity versus related neuropeptides (amylin, calcitonin, adrenomedullin, intermedin)[13]
- Highly specific binding prevents off-target effects
Dosing and Administration
Approved Dosing:
- 100 mg IV every 3 months (recommended starting dose)
- 300 mg IV every 3 months (for patients who may benefit from higher dose) 30-minute infusion duration regardless of dose[15] [16]
Administration Settings:
- Infusion centers
- Physician offices
- Hospital outpatient settings
- Home infusion (where appropriate)[16] [17]
Clinical Evidence: PROMISE Trials and Beyond
PROMISE-2: Chronic Migraine Pivotal Trial
The PROMISE-2 trial (NCT02974153) was a randomized, double-blind, placebo-controlled phase 3 study [2] evaluating eptinezumab in 1,072 adults with chronic migraine.
Study Population:
- 1,072 adults with chronic migraine
- Patients with ≥15 headache days per month, ≥8 migraine days
- Included patients with medication overuse headache
- Mean baseline migraine days: 16 per month
Primary Endpoint Results:
- 100 mg dose: 7.7 mean reduction in monthly migraine days vs 5.6 placebo (P<0.001)
- 300 mg dose: 8.2 mean reduction in monthly migraine days vs 5.6 placebo (P<0.001)
Key Secondary Endpoints:
- ≥50% Responder Rates: 57.6% (100 mg) and 61.4% (300 mg) vs 39.3% placebo
- ≥75% Responder Rates: 33.7% (100 mg) and 37.4% (300 mg) vs 17.1% placebo[2]
PROMISE-1: Episodic Migraine Supporting Data
The PROMISE-1 trial demonstrated efficacy in episodic migraine with 888 patients, showing significant reductions in monthly migraine days and establishing the broad efficacy profile of eptinezumab across the migraine [18] spectrum.
Real-World Evidence: PREVAIL Study
The 2-year open-label PREVAIL study (n=128) demonstrated sustained long-term efficacy and tolerability [3]:
- 78.1% of patients remained on treatment at 104 weeks
- Only 6.3% discontinued due to adverse events
- Sustained reduction in monthly migraine days maintained over 2 years
RESOLUTION Trial: Difficult-to-Treat Population
The phase IV RESOLUTION trial evaluated eptinezumab in patients with chronic migraine and medication overuse [19] headache who also received standardized patient education. Results showed statistically significant reductions in monthly migraine days within the first 4 weeks, demonstrating efficacy even in challenging patient populations.
Safety and Tolerability Profile
Clinical Trial Safety Data
Analysis of over 1,700 patients in pivotal trials demonstrates excellent tolerability.[4]
Most Common Adverse Reactions (≥2% incidence):
- Nasopharyngitis: 6-8% (vs 6% placebo)
- Hypersensitivity reactions: 1-2% (vs 0% placebo)
Discontinuation Rates:
- <2% of patients discontinued treatment due to adverse events[6]
- Comparable to placebo in most studies
Hypersensitivity Reactions [20] [6]
While hypersensitivity reactions can occur, they are generally mild and manageable:
- Most occur during or shortly after infusion
- Include symptoms such as flushing, pruritus, urticaria
- Serious reactions (anaphylaxis) are rare but reported in post-marketing
- Physicians can readily manage reactions with standard protocols
Long-Term Safety
2-Year PREVAIL Study Safety Outcomes:
- 14% of patients reported at least one study drug-related adverse event
Most common:
- hypersensitivity reaction (4%) and fatigue (3%)
- 18% developed anti-eptinezumab antibodies;
- 39% of those developed neutralizing antibodies
- Antibody formation did not affect efficacy or safety profile[4]
Contraindications and Precautions
Contraindications:
- Known hypersensitivity to eptinezumab-jjmr or excipients
Precautions:
- Monitor for hypersensitivity reactions during and after infusion
- Consider cardiovascular status in patients with significant cardiovascular disease
Clinical Advantages for Physicians
Rapid Onset of Action
Day 1 Efficacy:
- Significant reduction in migraine prevalence observed on Day 1 post-infusion[2] [21]
- 42.3% of placebo patients vs 28.6% (100 mg) and 27.8% (300 mg) eptinezumab patients experienced migraine on Day 1
- Benefits maintained throughout the 3-month dosing interval
Sustained Prevention
Quarterly Dosing Benefits:
- Eliminates daily medication compliance issues
- Reduces pill burden and potential drug interactions
- Provides consistent therapeutic levels for 3 months
- No “wearing off” effect commonly seen with monthly treatments[5]
Superior Bioavailability
100% Drug Delivery:
- IV administration ensures complete bioavailability
- Avoids first-pass metabolism and absorption variability
- Immediate therapeutic plasma concentrations
- More predictable clinical response
Patient Selection Advantages
Broad Applicability:
- Effective in treatment-naive and treatment-experienced patients
- Suitable for patients with medication overuse headache
- No significant drug interactions reported
- Can be used in patients unable to tolerate oral medications
Patient-Reported Outcomes and Quality of Life
Functional Improvement
Clinical trials demonstrate significant improvements in patient-reported outcomes[22]:
HIT-6 (Headache Impact Test) Improvements:
- Clinically meaningful reductions in headache-related disability
- Improvements sustained through 6-month follow-up
- Normalization of quality of life measures across multiple domains
SF-36 Quality of Life Measures:
- Significant improvements in bodily pain, social functioning, and physical functioning ≥75% responders showed quality of life improvements to normative population levels[22]
Real-World Patient Experience
Post-marketing data show substantial improvements in daily functioning[23]:
Patients reported >2× the number of monthly “good days” after starting VYEPTI Higher satisfaction with various elements of daily living and well-being Reduced migraine-related disability and work productivity loss[19]
Economics and Value
Direct Cost Considerations:
Quarterly dosing reduces administrative burden compared to monthly treatments Potential reduction in acute medication use and healthcare utilization
Indirect Cost Benefits:
- Significant reduction in missed workdays
- Decreased emergency department visits
- Improved work productivity and functional capacity
- Reduced caregiver burden
Comparative Effectiveness with Other CGRP Inhibitors
CGRP Monoclonal Antibody Class Comparison
Unique Advantages of VYEPTI:
| Feature | VYEPTI | Other CGRP mAbs |
| Route of Administration | Intravenous | Subcutaneous |
| Dosing Frequency | Every 3 months | Monthly |
| Bioavailability | 100% | 50-82% |
| Onset of Action | Day 1 | 5-7 days |
| Peak Concentration | 30 minutes | 5-7 days |
| Injection Site Reactions | None | Common |
Clinical Trial Cross-Study Comparisons
While head-to-head studies are limited, indirect comparisons suggest :
- Faster onset of action compared to subcutaneous alternatives
- Lower patient-reported “wearing off” effects
- Superior convenience with quarterly dosing
- Comparable or superior efficacy rates in chronic migraine populations
Implementation in Clinical Practice
Patient Selection Criteria
Ideal Candidates for VYEPTI:
- Chronic migraine patients (≥15 headache days/month)
- Patients with inadequate response to 2-3 prior preventive treatments
- Patients with medication overuse headache
- Patients preferring less frequent dosing
- Patients with injection site reactions to subcutaneous therapies
- Patients with compliance challenges with daily medications
Treatment Initiation Protocol
Pre-Treatment Assessment:
- Confirm chronic migraine diagnosis using ICHD-3 criteria
- Document baseline migraine frequency using headache diary
- Review cardiovascular history and current medications
- Assess previous preventive treatment responses
- Discuss treatment expectations and infusion logistics
Infusion Day Protocol:
- Pre-medication not routinely required but available if needed
- Monitor vital signs and patient comfort during 30-minute infusion
- Observe for 30 minutes post-infusion for hypersensitivity reactions
- Schedule next quarterly appointment before discharge
- Provide patient education materials and support contacts
Monitoring and Follow-Up
Efficacy Assessment:
- Headache diary review at 4-week intervals
- HIT-6 or MIDAS assessments quarterly
- Patient Global Impression of Change evaluations
- Assessment for ≥50% reduction in monthly migraine days
Safety Monitoring:
- Review for adverse events at each visit
- Monitor for delayed hypersensitivity reactions
- Assess for any changes in cardiovascular status
- Document antibody development if efficacy decreases
Future Perspectives and Research Directions
Ongoing Studies
SUNRISE Trial: Phase III trial confirming efficacy in Asian populations with chronic migraine , expanding the global evidence base for VYEPTI’s effectiveness across diverse patient populations.
Long-Term Extension Studies: Ongoing research continues to evaluate long-term safety and efficacy beyond 2 years, with preliminary data suggesting sustained benefits and acceptable safety profiles.
Potential Expanded Indications
Areas of Investigation:
- Episodic migraine prevention in high-frequency patients
- Combination therapies with other migraine preventives
- Acute treatment applications during migraine attacks
- Cluster headache prevention
Personalized Medicine Approaches
Future research may identify biomarkers to predict treatment response, optimize dosing strategies, and personalize CGRP inhibitor selection based on individual patient characteristics and genetic profiles.
Conclusions and Clinical Recommendations
VYEPTI (eptinezumab-jjmr) represents a significant advancement in chronic migraine prevention, offering Physicians a highly effective, well-tolerated therapeutic option with unique clinical advantages. The combination of rapid onset, sustained efficacy, superior bioavailability, and excellent tolerability profile positions VYEPTI as an excellent first-line or alternative treatment choice for appropriate chronic migraine patients.
Key Clinical Takeaways for Physicians:
1. Rapid and Sustained Efficacy: VYEPTI provides meaningful migraine reduction as early as Day 1, with benefits sustained through quarterly dosing intervals.
2. Superior Tolerability: <2% discontinuation rate due to adverse events, with manageable hypersensitivity reactions being the primary safety consideration.
3. Patient-Centered Benefits: Quarterly infusions eliminate daily medication burden, reduce pill fatigue, and provide consistent therapeutic levels without “wearing off” effects.
4. Broad Applicability: Effective across diverse chronic migraine populations, including those with medication overuse headache and multiple prior treatment failures.
5. Economic Value: Potential for significant indirect cost savings through reduced healthcare utilization, improved productivity, and enhanced quality of life.
6. Practice Integration: Straightforward administration protocol with established infusion networks and comprehensive patient support services.
For Physicians treating chronic migraine patients, VYEPTI offers an evidence-based therapeutic option that addresses many limitations of traditional preventive therapies while providing superior clinical outcomes and patient satisfaction.
The robust clinical evidence, favorable safety profile, and unique pharmacological advantages make VYEPTI a compelling choice for improving patient outcomes in chronic migraine management.
References and Supporting Evidence
This white paper is based on extensive clinical evidence from peer-reviewed publications, regulatory submissions, and real-world studies.
Physicians are encouraged to review the complete prescribing information and consult current clinical guidelines when considering VYEPTI for their chronic migraine patients.
Key Clinical Studies:
PROMISE-2: Pivotal chronic migraine trial (N=1,072)
PROMISE-1: Episodic migraine trial (N=888)
PREVAIL: 2-year long-term safety and efficacy study
RESOLUTION: Difficult-to-treat population study
Regulatory Status:
FDA approved February 21, 2020
EMA approved 2021
Indicated for migraine prevention in adults
References
- FDA Approves Eptinezumab–the Only Infusion Treatment for Migraine Prevention
URL: https://practicalneurology.com/news/fda-approves-eptinezumab-the-only-infusion-treatment-for-migraine-prevention/2469166/ - Vyepti (eptinezumab): Uses, Side Effects, Interactions – WebMD
URL: https://www.webmd.com/drugs/2/drug-178883/vyepti-intravenous/details - New data demonstrates robust efficacy of Vyepti® (eptinezumab)
URL: https://www.prnewswire.com/news-releases/new-data-demonstrates-robust-efficacy-of-vyepti-eptinezumab-in-otherwise-difficult-to-treat-patients-with-severe-migraine-302487652.html - FDA approves eptinezumab-jjmr for preventative treatment of migraine
URL: https://www.antibodysociety.org/food-and-drug-administration/fda-approves-eptinezumab-jjmr-for-preventative-treatment-of-migraine/ - Eptinezumab: Uses, Interactions, Mechanism of Action – DrugBank
URL: https://go.drugbank.com/drugs/DB14040 - Efficacy & Patient Outcomes – VYEPTI® (eptinezumab-jjmr) IV Infusion
URL: https://www.vyeptihcp.com/efficacy-and-patient-outcomes - Eptinezumab-jjmr (Vyepti) – Medical Clinical Policy Bulletins | Aetna
URL: https://www.aetna.com/cpb/medical/data/900_999/0970.html - Vyepti, eptinezumab – European Medicines Agency
URL: https://www.ema.europa.eu/en/documents/product-information/vyepti-epar-product-information_en.pdf - Clinical Study Results for VYEPTI® IV Migraine Treatment
URL: https://www.vyepti.com/vyepti-study-results - Breaking New Ground in Migraine Prevention: Eptinezumab-jjmr
URL: https://www.pharmacytimes.com/view/breaking-new-ground-in-migraine-prevention-eptinezumab-jjmr - The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine – PMC
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC9294119/ - New data from phase III trial confirms efficacy of Vyepti
URL: https://www.prnewswire.com/news-releases/new-data-from-phase-iii-trial-confirms-efficacy-of-vyepti-eptinezumab-in-asian-population-with-chronic-migraine-302487648.html - Vyepti (eptinezumab) – Medical Drug Clinical Criteria
URL: https://www.carelonrx.com/ms/pharmacyinformation/Vyepti.pdf - A Review of Eptinezumab Use in Migraine – PMC
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8446121/ - Study Details | NCT04418765 | ClinicalTrials.gov
URL: https://www.clinicaltrials.gov/study/NCT04418765 - VYEPTI (eptinezumab-jjmr) – FDA Label
URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf - VYEPTI® (eptinezumab-jjmr) IV Infusion | Powerful Migraine
URL: https://www.vyeptihcp.com - Long-term effectiveness of eptinezumab in patients with migraine
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10662788/ - VYEPTI® (eptinezumab-jjmr) IV Migraine Prevention Medicine
URL: https://www.vyepti.com - Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies
URL: https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/ - Efficacy and safety of eptinezumab in patients with chronic migraine
URL: https://www.neurology.org/doi/10.1212/WNL.0000000000009169 - VYEPTI Case Study – Neurology Live
URL: https://www.neurologylive.com/vyepti_interactive_case - Emgality, Ajovy, Vyepti or Aimovig CGRP monoclonal antibodies
URL: https://virtualheadachespecialist.com/battle-of-the-monoclonal-antibody-cgrp-antagonists-aimovig-vs-ajovy-vs-emgality-vs-vyepti-what-are-the-differences-and-which-is-best-for-you/ - Safety & tolerability – VYEPTI® (eptinezumab-jjmr) IV Infusion
URL: https://www.vyeptihcp.com/safety-and-tolerability - 8 CGRP Inhibitors for Migraine Treatment and Prevention – GoodRx
URL: https://www.goodrx.com/classes/cgrp-receptor-antagonists/cgrp-inhibitors-for-migraines - Effects of Intravenous Eptinezumab vs Placebo on Headache Pain
URL: https://jamanetwork.com/journals/jama/fullarticle/2781053 - Side Effects With VYEPTI® (eptinezumab-jjmr) Treatment
URL: https://www.vyepti.com/vyepti-side-effects - CGRP Monoclonal Antibodies (MABs): Summary and Effectiveness
URL: https://migrainecanada.org/cgrp-monoclonal-antibodies-mabs-summary-and-effectiveness/ - American Headache Society Position Statement: Calcitonin Gene
URL: https://www.migrainedisorders.org/ahs-statement-cgrp/ - Efficacy and safety of eptinezumab in patients with chronic migraine
URL: https://pubmed.ncbi.nlm.nih.gov/32209650/ - How does eptinezumab differ from other migraine treatments?
URL: https://www.youtube.com/watch?v=bZSnNpGrDTo - Eptinezumab improved patient‐reported outcomes
URL: https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14434 - Comprehensive safety analysis of adverse events
URL: https://www.nature.com/articles/s41598-025-09490-1 - Clinical Review – Eptinezumab (Vyepti) – NCBI Bookshelf
URL: https://www.ncbi.nlm.nih.gov/books/NBK596319/ - Eptinezumab for Prevention of Chronic Migraine – Neurology
URL: https://www.neurology.org/doi/10.1212/WNL.92.15_supplement.P2.10-006 - Vyepti and Cost: Financial Assistance Options and More – Healthline
URL: https://www.healthline.com/health/drugs/vyepti-cost - Burden of migraine in the United States: disability and economic costs
URL: https://pubmed.ncbi.nlm.nih.gov/10219926/ - Financial Assistance & Support for VYEPTI® (eptinezumab-jjmr)
URL: https://www.vyepti.com/financial-assistance - Patient-reported outcomes, health-related quality of life
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8903490/ - Factors Associated with Direct Health Care Costs
URL: https://www.jmcp.org/doi/10.18553/jmcp.2017.23.11.1169 - Vyepti: Cost, dosage, use for migraine, and more
URL: https://www.medicalnewstoday.com/articles/drugs-vyepti - Lundbeck showcases new clinical migraine data
URL: https://www.prnewswire.com/news-releases/lundbeck-showcases-new-clinical-migraine-data-including-long-term-preventive-effectiveness-of-vyepti-eptinezumab-in-patients-severely-impacted-by-migraine-302553630.html - Burden of Migraine in the United States: Disability and Economic
URL: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/485012 - Data Show Sustained Improvement in Migraine Symptoms
URL: https://www.drugtopics.com/view/data-show-sustained-improvement-in-migraine-symptoms-with-eptinezumab - Summary of Outcome Measures – NCBI
URL: https://www.ncbi.nlm.nih.gov/books/NBK596319/table/tr8269861151140743_ch01_t36/?report=objectonly - Real‐world assessment of the relationship between migraine
URL: https://headachejournal.onlinelibrary.wiley.com/doi/full/10.1111%2Fhead.14289 - Pharmacoeconomic Review – Eptinezumab (Vyepti) – NCBI
URL: https://www.ncbi.nlm.nih.gov/books/NBK596321/ - The VYEPTI experience: Real-world data & peer insights
URL: https://www.vyeptihcp.com/real-vyepti-experience - Unveiling the Public Economic Burden of Migraine in Argentina
URL: https://jheor.org/article/133639-unveiling-the-public-economic-burden-of-migraine-in-argentina - Long-term benefits of Vyepti confirmed by new data
URL: https://firstwordpharma.com/story/5752180 - Migraine-Related Disability Directly Impacts Health Care Utilization
URL: https://www.neurologylive.com/view/migraine-related-disability-directly-impacts-health-care-utilization-episodic-migraine - Lundbeck to Present New Clinical and Real-World VYEPTI
URL: https://www.lundbeck.com/us/newsroom/2023/lundbeck-to-present-new-clinical-and-real-world-vyepti-data - Vyepti Infusions for Chronic Migraine Treatment – IVX Health
URL: https://ivxhealth.com/therapies/vyepti/ - Calcitonin gene-related peptide (CGRP): Role in migraine
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC7050542/ - Chronic migraine classification: current knowledge and future
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC3208036/ - Vyepti Infusion | Migraine Infusions | Medical Infusion Center
URL: https://www.luxinfusion.com/vyepti - CGRP physiology, pharmacology, and therapeutic targets
URL: https://journals.physiology.org/doi/abs/10.1152/physrev.00059.2021 - Diagnosis and management of migraine in ten steps
URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC8321897/ - What to Expect With VYEPTI® Intravenous (IV) Migraine Treatment
URL: https://www.vyepti.com/what-to-expect - Role of Calcitonin Gene-Related Peptide on the Gastrointestinal
URL: https://www.neurology.org/doi/10.1212/WNL.0000000000201332 - The International Classification of Headache Disorders
URL: https://ihs-headache.org/wp-content/uploads/2020/05/ICHD-3-Pocket-version.pdf - Why VYEPTI® IV Migraine Preventive Treatment
URL: https://www.vyepti.com/why-iv-treatment - Role of CGRP Signaling in Migraine Pathophysiology
URL: https://www.scienceofmigraine.com/pathophysiology/cgrp - 1.3 Chronic migraine – ICHD-3
URL: https://ichd-3.org/1-migraine/1-3-chronic-migraine/ - Dosing Information & Administration | VYEPTI®
URL: https://www.vyeptihcp.com/dosing-and-administration - CGRP and the Trigeminal System in Migraine
URL: https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.13529 - Guidelines /ICHD – International Headache Society
URL: https://ihs-headache.org/en/resources/guidelines/ - Vyepti Patient Guide PDF – FlexCare Infusion Centers
URL: https://flexcareinfusion.com/docs/Vyepti-Patient-Guide.pdf - CGRP and migraine: from bench to bedside
URL: https://www.sciencedirect.com/science/article/pii/S0035378721006068- Migraine – ICHD-3
URL: https://ichd-3.org/1-migraine/
- Migraine – ICHD-3
- Access VYEPTI Resources & Support
URL: https://www.vyeptihcp.com/access-vyepti - CGRP and Migraine: What Have We Learned From Measuring
URL: https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2022.930383/full
